

IFW

# ARNOLD & PORTER LLP

202.942.5000  
202.942.5999 Fax  
555 Twelfth Street, NW  
Washington, DC 20004-1206



July 31, 2006

Mail Stop Issue Fee  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Re: U.S. Application No. 10/500,319  
371 Filing Date: November 22, 2004  
Title: *Indoles as NAALADase Inhibitors*  
Applicants: Takashi TSUKAMOTO *et al.*  
Atty. Docket: 20595.128

Sir:


The following documents are forwarded herewith for appropriate action by the U.S. Patent and Trademark Office:

1. a Substance of Interview; and
2. a return postcard.

Please stamp the attached postcard with the filing date of these documents and return it to our courier.

In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned. Applicants do not believe any fees are due in conjunction with this filing. However, if any fees are required in the present application, including any fees for extensions of time, then the Commissioner is hereby authorized to charge such fees to Arnold & Porter LLP Deposit Account No. 50-2387 referencing matter number 20595.128. A duplicate copy of this letter is enclosed.

Respectfully submitted,

  
David R. Marsh (Reg. No. 41,408)  
Suet M. Chong (Reg. No. 38,104)

Attachments

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Takashi TSUKAMOTO *et al.*

Appl. No.: 10/500,319

371 Filing Date: November 22, 2004

Title: *Indoles as NAALADase Inhibitors*



Art Unit: 1626

Examiner: Nyeemah GRAZIER

Atty. Docket: 20595.128

Confirmation No.: 9108

## Substance of Interview

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:


Applicants thank the Examiner for extending to the undersigned the courtesy of a telephonic interview on June 15, 2006. During the interview, the Examiner and the undersigned agreed to cancel withdrawn claims 6 to 44, and to add new dependent pharmaceutical composition claims 47 to 49:

47. The pharmaceutical composition of claim 45, wherein:  
A<sup>1</sup>, A<sup>2</sup>, A<sup>3</sup> and A<sup>4</sup> are independently hydrogen or -COOH;  
R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> are each hydrogen; and  
R<sup>5</sup> is hydrogen, phenyl, benzyl or phenylethyl, wherein said phenyl, benzyl or phenylethyl are independently substituted with one or more substituent(s).
48. The pharmaceutical composition of claim 47, wherein R<sup>5</sup> is benzyl substituted with one or more substituent(s) independently selected from the group consisting of carboxy, halo, C<sub>1</sub>-C<sub>4</sub> alkyl and C<sub>1</sub>-C<sub>4</sub> alkoxy.

49. The pharmaceutical composition of claim 45, wherein the compound is an enantiomer or an enantiomer-enriched mixture.

The Examiner and the undersigned agreed that the aforementioned amendments would place the application in condition for allowance.

Respectfully submitted,

  
Suet M. Chong (Reg. No. 38,104)

Date: July 31, 2006  
ARNOLD & PORTER LLP  
555 Twelfth Street, N.W.  
Washington, DC 20004-1206  
202.942.5000 telephone  
202.942.5999 facsimile